"Abbott" TDM complex correction solution
Taiwan·Risk Class 2·B.R.A.H.M.S GmbH;; MICROGENICS CORPORATION·Registered Apr 15, 2019 – Apr 15, 2029Active- Analysis ID
- e05de0393fbcfdc693587a36db367835
- Customs Code
- DHA05603240609
- Manufacturer
- B.R.A.H.M.S GmbH;; MICROGENICS CORPORATION
- Manufacturer Country
- United States;;Germany
- Authorized Representative
- ABBOTT LABORATORIES SERVICES LLC TAIWAN BRANCH (U.S.A.)
- Intended Use
- This product is suitable for in vitro diagnostics, with Alinity c system for the detection of digheroid, gentamicin, diphenyllactamuria and vancomycin in human serum or plasma. This product (specification: 08P7403) is suitable for in vitro diagnostics, with the Alinity c system for the calibration and detection of Amikacin, foxglove, Gentamicin, phenylbarbital, diphenyllactium, Theophylline, and Valproic Acid) and Vancomycin for analysis.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A.1150 Calibrated Products
- Import Information
- Input;; Contract manufacturing
- Registration Date
- Apr 15, 2019
- Expiry Date
- Apr 15, 2029
Top companies providing products similar to ""Abbott" TDM complex correction solution"
Recently registered similar products
Access comprehensive regulatory information for "Abbott" TDM complex correction solution in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number e05de0393fbcfdc693587a36db367835 and manufactured by B.R.A.H.M.S GmbH;; MICROGENICS CORPORATION. The authorized representative in Taiwan is ABBOTT LABORATORIES SERVICES LLC TAIWAN BRANCH (U.S.A.).
This page provides complete technical specifications, regulatory compliance details, 1 companies making similar products including MICROGENICS CORPORATION, and 1 recent registrations in the same category. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.